Skip to main content
SpringerLink
Log in

Nonsteroidal antiinflammatory agents in chemoprevention of colorectal cancer at what cost?

  • Gastrointestinal Oncology
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

The objective was to provide a comparison of the known toxicities of nonsteroidal antiinflammatory drugs (NSAIDS) and the likelihood of benefit from colorectal cancer (CRC) chemoprevention attributed to them. Chemoprevention trials require large numbers of subjects followed over many years and are therefore very expensive and difficult. Hence, it is important that agents tested in these trials have a realistic expectation of actual use in the population. Data sources were published literature on the toxicity and CRC chemopreventive activity of NSAIDS. Presently available NSAIDS, used at their usual therapeutic doses, have a serious toxicity rate that quickly exceeds any benefit from CRC prevention. In contrast, low-dose aspirin is worth evaluating, especially because of the potential for simultaneous cardiovascular risk reduction. Possibly, low doses of other NSAIDS may have benefit, but this remains unproven. Synthesis of other NSAIDS, with less toxicity, is another approach towards making the toxicity-benefit ratio more favorable for the use of these agents for CRC prevention.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Boring CC, Squires TS, Tong T: Cancer statistics, 1993. 43:7–26, 1993

    Google Scholar 

  2. Smart CR: Screening and diagnosis. Cancer 70:1246–1251, 1992

    PubMed  Google Scholar 

  3. Eddy DM: Screening for colorectal cancer. Ann Intern Med 113:373–384, 1990

    PubMed  Google Scholar 

  4. Greenwald P: Colon cancer overview. Cancer 70:1206–1215, 1992

    PubMed  Google Scholar 

  5. Greenberg ER, Barron JA: Prospects for preventing colorectal cancer death. J Natl Cancer Inst 85:1182–1184, 1993 (editorial)

    PubMed  Google Scholar 

  6. Craven PA, DeRubertis FR: Effect of aspirin on 1,2-dimethyl/hydrazine-induced colonic neoplasia. Gastroenterology 96:A134, 1992

    Google Scholar 

  7. Craven PA, DeRubertis FR: Effect of aspirin on 1,2-dimethyl/hydrazine-induced colonic carcinogenesis. Carcinogenesis 13:541–546, 1992

    PubMed  Google Scholar 

  8. Reddy B, Maruyama H, Kelloff G: Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal anti-inflammatory drug, during different stages of rat colon tumor development. Cancer Res 47:5340–5346, 1987

    PubMed  Google Scholar 

  9. Narisawa T, Sato M, Tani M, Kudo T, Takahashi T, Goto A: Inhibition of development of methyl nitrosurea-induced rat colon tumors by indomethacin treatment. Cancer Res 4:1954–1957, 1981

    Google Scholar 

  10. Pollard M, Luckert PH: Treatment of chemically induced-intestinal cancer with indomethacin. Proc Soc Exp Biol Med 167:161–164, 1981

    PubMed  Google Scholar 

  11. Moorghen M, Ince P, Finney KJ, Sunter JP, Appleton DR, Watson AJ: A protective effect of sulindac against chemically-induced primary colonic tumors in mice. J Pathol 156:341–347, 1988

    PubMed  Google Scholar 

  12. Skinner S, Penney A, Penney G, O'Biren PE: Sulindac inhibits the rate of growth and appearance of colon tumors in the rat. Arch Surg 126:1094–1096, 1991

    PubMed  Google Scholar 

  13. Hixson LJ, Trujillo MA, Hansen K, Ritchie J, Earnest D: Effect of oral olsalazine sodium and aspirin on azoxymethane induced colon neoplasia in the rat. Gastroenterology 102:A363, 1992

    Google Scholar 

  14. Waddell WR, Loughry RW: Sulindac for polyposis of the colon. J Surg Oncol 24:83–87, 1983

    PubMed  Google Scholar 

  15. Waddell WR, Ganser GF, Cerise EJ, Loughry RW: Sulindac for polyposis of the colon. Am J Surg 14:153–157, 1989

    Google Scholar 

  16. Labayle D, Fischer D, Vielh P, Drouhin F, Pariente A, Bories C: Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 101:635–639, 1991

    PubMed  Google Scholar 

  17. Rigau J, Pique J, Rubio E, Planas R, Tarrech JM, Bordas JM: Effects of long-term sulindac therapy on colonic polyposis. Ann Intern Med 115:952–954, 1991

    PubMed  Google Scholar 

  18. Gonzaga RAD, Lima FR, Carneiro S, Maciel J, Junior MA: Sulindac treatment for familial polyposis coli. Lancet 1:751, 1985

    Google Scholar 

  19. Itoh H, Ikeda S, Oohata Y: Treatment of desmoid tumors in Gardner's syndrome: Report of a case. Dis Colon Rectum 31:459–461, 1988

    PubMed  Google Scholar 

  20. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson RC, Offerhaus JA: Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328:1313–1316, 1993

    PubMed  Google Scholar 

  21. Kune GA, Kune S, Watson LF: Colorectal cancer risk, chronic illnesses, operations, and medications: Case control results from the Melbourne Colorectal Cancer Study. Cancer 48:4399–4304, 1988.

    PubMed  Google Scholar 

  22. Rosenberg L, Palmer JR, Zaubert AG, Warshauer ME, Stolley PD, Shapiro S: A hypothesis: Nonsteroidal anti-inflammatory drugs reduce the incidence of large bowel cancer. J Natl Cancer Inst 83:355–358, 1991

    PubMed  Google Scholar 

  23. Thun MJ, Nanboodiri MM, Heath CW: Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325:1593–1596, 1991

    PubMed  Google Scholar 

  24. Paganini-Hill A, Chao A, Ross RK, Henderson BE: Aspirin use and chronic diseases: a cohort study of the elderly. Br Med J 229:1247–1250, 1989

    Google Scholar 

  25. Gridley G, McLaughlin JK, Ekbom A, Klareskog L, Adami HO, Hacker DG, Hoover R, Fraumeni JF: Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 85:307–311, 1993

    PubMed  Google Scholar 

  26. Greenberg ER, Baron JA, Freeman DH, Mandel JS, Haile R: Reduced risk of large-bowel adenomas among aspirin users. J Natl Cancer Inst 85:912–916, 1993

    PubMed  Google Scholar 

  27. Gann PH, Manson JE, Glynn RJ, Buring JE, Hennekens CH: Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst 85:1120–1124, 1993

    Google Scholar 

  28. Suh O, Meltlin C, Petrelli N: Aspirin use, cancer and polyps of the large bowel. Cancer 72:1171–1177, 1993

    PubMed  Google Scholar 

  29. JE Dalen, J Hirsh (eds). Third ACCP Consensus Conference on Antithrombotic Therapy. Chest 102:303s–336s, 1992

  30. Gabriel SE, Jaakkimainen L, Bombardier C: Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. Ann Intern Med 115:787–796, 1991

    PubMed  Google Scholar 

  31. Loeb DS, Ahlquist DA, Talley NJ: Management of gastroduodenopathy associated with use of nonsteroidal anti-inflammatory drugs. Mayo Clin Proc 67:354–364, 1992

    PubMed  Google Scholar 

  32. Labeling revisions for NSAIDs. FDA Drug Bill 19:3–4, 1989

    Google Scholar 

  33. Allison MC, Howatson AG, Torrance CJ, Lee FD, Russell RI, Ray WA: Gastrointestinal damage associated with the use of nonsteroidal anti-inflammatory drugs. N Engl J Med 327:749–754, 1990

    Google Scholar 

  34. Griffin MR, Piper JM, Daugherty JR, Snowden M, et al: Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 114:257–263, 1991

    PubMed  Google Scholar 

  35. Levy M, Miller MS, Kaufman DW, Siskind V, Schwingl P, Rosenberg L, Strom B, Shapiro S: Major upper gastrointestinal tract bleeding. Relations to the use of aspirin and other non-narcotic analgesia. Arch Intern Med 148:281–285, 1988

    PubMed  Google Scholar 

  36. Naschitz JE, Yeshurun D, Odeh MI: Overt gastrointestinal bleeding in the course of chronic low-dose aspirin administration for secondary prevention of arterial occlusive disease. Am J Gastroenterol 85:408–411, 1990

    PubMed  Google Scholar 

  37. Graham DY, Smith JL: Aspirin and the stomach. Ann Intern Med 104:390–398, 1986

    PubMed  Google Scholar 

  38. Gibson GR, Whitacre EB, Ricotti CA: Colitis induced by nonsteroidal anti-inflammatory drugs. Report of four cases and review of the literature. Arch Intern Med 152:625–632, 1992

    PubMed  Google Scholar 

  39. Prichard PJ, Kitchingma GK, Walt RP: Human gastric mucosal bleeding induced by low dose aspirin, but not warafin. Br Med J 298:493–496, 1989

    Google Scholar 

  40. Prichard PJ, Kitchingma GK, Hawkey CJ: Gastric mucosal bleeding: What dose of aspirin is safe? Gut 28:A1401, 1987

  41. Aoll AH, Weinstein WM, Kurata J, MacCarthy O: Nonsteroidal anti-inflammatory drugs and peptic ulcer disease. Ann Intern Med 114:307–319, 1991

    PubMed  Google Scholar 

  42. Shorrock CJ, Langman MJS, Warlow C: Risks ofupper GI bleeding during TIA prophylaxis with aspirin. Gastroenterology 102:A165, 1992

    Google Scholar 

  43. Kurata JH, Abbey DE: The effect of chronic aspirin use on duodenal and gastric ulcer hospitalizations. J Clin Gastroenterol 12:260–266, 1990

    PubMed  Google Scholar 

  44. Langman MJS, Morgan L, Worrall A: Use of antiinflammatory drugs by patients admitted with small or large bowel perfrations and hemorrage. Br Med J 290:347–349, 1985

    Google Scholar 

  45. Steering Committee of the Physicians' Health Study: Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 321:129–135, 1989

    Google Scholar 

  46. Clive DM, Stoff JS: Renal syndromes associated with non-steroidal anti-inflammatory drugs. N Engl J Med 310:563–572, 1984

    PubMed  Google Scholar 

  47. Carmichael J, Shankel SW: Effects of nonsteroidal anti-inflammatory drugs on prostaglandins and renal function. Am J Med 78:992–1000, 1985

    PubMed  Google Scholar 

  48. Sidransky D, Tokino T, Hamilton SH, et al: Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 256:102–105, 1992

    PubMed  Google Scholar 

  49. Terpstra O, VanBlankenstein M, Dees J, Eilers GAM: Abnormal pattern of cell proliferation in the entire colonic mucosa of patients with colon adenoma or cancer. Gastroenterology 92:704–708, 1987

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. From the Section of Gastroenterology, and of Hematology-Oncology, Tucson VA Medical Center, 3601 S. 6th Avenue, 85723, Tucson, Arizona

    M. Angelo Trujillo MD, Harinder S. Garewal MD, PhD & Richard E. Sampliner MD

Authors
  1. M. Angelo Trujillo MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Harinder S. Garewal MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Richard E. Sampliner MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Angelo Trujillo, M., Garewal, H.S. & Sampliner, R.E. Nonsteroidal antiinflammatory agents in chemoprevention of colorectal cancer at what cost?. Digest Dis Sci 39, 2260–2266 (1994). https://doi.org/10.1007/BF02090382

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02090382

Key words

Search

Navigation